Evidence map›Paper›PMID 37300986›Full record

ArticleBreast (Edinburgh, Scotland)2023

Development of the HT&Me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life.

Sarah-Jane F Stewart, Joanna Slodkowska-Barabasz, Lucy McGeagh, Zoe Moon, Jo Brett, Mary Wells, Morven C Brown, Mark Turner, Robert Horne, Deborah Fenlon and 9 more

Open access · goldAbstract read
In one paragraph

Article in Breast (Edinburgh, Scotland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Sarah-Jane F StewartResearch Department of Practice and Policy, UCL School of Pharmacy, University College London, UK.
Joanna Slodkowska-BarabaszOxford Institute of Nursing, Midwifery and Allied Health Research, Oxford Brookes University, UK.
Lucy McGeaghOxford Institute of Nursing, Midwifery and Allied Health Research, Oxford Brookes University, UK.
Zoe MoonResearch Department of Practice and Policy, UCL School of Pharmacy, University College London, UK.
Jo BrettOxford Institute of Nursing, Midwifery and Allied Health Research, Oxford Brookes University, UK.
Mary WellsImperial College Healthcare NHS Trust, UK.
Morven C BrownPopulation Health Sciences Institute, Newcastle University, UK; Newcastle University Centre for Cancer, Newcastle University, UK.
Mark TurnerResearch Software Engineering, Newcastle University, UK.
Robert HorneResearch Department of Practice and Policy, UCL School of Pharmacy, University College London, UK.
Deborah FenlonFaculty of Medicine and Life Science, Swansea University, UK.
Farah RehmanImperial College Healthcare NHS Trust, UK.
Henry CainNewcastle Upon Tyne Hospitals NHS Foundation Trust, UK.
Peter DonnellySouth Devon Healthcare NHS Foundation Trust, UK.
Victoria HarmerImperial College Healthcare NHS Trust, UK.
Lesley TurnerPatient and Public Involvement Representatives, UK.
Jan RosePatient and Public Involvement Representatives, UK.
Linda SharpPopulation Health Sciences Institute, Newcastle University, UK; Newcastle University Centre for Cancer, Newcastle University, UK.
Eila WatsonOxford Institute of Nursing, Midwifery and Allied Health Research, Oxford Brookes University, UK. Electronic address: ewatson@brookes.ac.uk.
SWEET Research Team
Oxford Brookes University · GBImperial College Healthcare NHS Trust · GBNewcastle University · GBUniversity College London · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNorthern Devon Healthcare NHS Trust · GBSwansea University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common cancer in women worldwide. Approximately 80% of breast cancers are oestrogen receptor positive (ER+). Patients treated surgically are usually recommended adjuvant endocrine therapy (AET) for 5-10 years. AET significantly reduces recurrence, but up to 50% of women do not take it as prescribed.

objectiveTo co-design and develop an intervention to support AET adherence and improve health-related quality-of-life (QoL) in women with breast cancer.

methodsDesign and development of the HT&Me intervention took a person-based approach and was guided by the Medical Research Council framework for complex interventions, based on evidence and underpinned by theory. Literature reviews, behavioural analysis, and extensive key stakeholder involvement informed 'guiding principles' and the intervention logic model. Using co-design principles, a prototype intervention was developed and refined.

resultsThe blended tailored HT&Me intervention supports women to self-manage their AET. It comprises initial and follow-up consultations with a trained nurse, supported with an animation video, a web-app and ongoing motivational 'nudge' messages. It addresses perceptual (e.g. doubts about necessity, treatment concerns) and practical (e.g. forgetting) barriers to adherence and provides information, support and behaviour change techniques to improve QoL. Iterative patient feedback maximised feasibility, acceptability, and likelihood of maintaining adherence; health professional feedback maximised likelihood of scalability.

conclusionsHT&Me has been systematically and rigorously developed to promote AET adherence and improve QoL, and is complemented with a logic model documenting hypothesized mechanisms of action. An ongoing feasibility trial will inform a future randomised control trial of effectiveness and cost-effectiveness.

Indexed as

Breast NeoplasmsChemotherapy, AdjuvantFemaleHumansMedication AdherenceQuality of Life

Identifiers

PMID37300986
PMCPMC10382955
OpenAlexW4378575038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.